Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat

Epilepsy Research

Volumn 34, Issue 2-3, 1999, Pages 161-168

  Doheny, H C ^a   Ratnaraj, N ^a   Whittington, M A ^b   Jefferys, J G R ^c   Patsalos, P N ^a  

^a Epilepsy Res Grp Inst N   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Central nervous system; Epilepsy; Free fraction; Freely behaving rats; New antiepileptic drug

Indexed keywords

ETIRACETAM;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CONVULSION; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; MALE; OSMOLAR CONCENTRATION; PIRACETAM; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0032942934     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(98)00104-1     Document Type: Article

References (25)

1. Danhof M., Levy G. Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J. Pharmocol. Exp. Ther. 229:1984;44-50.
2. Dingemanse J., van Bree J.B.M.M., Danhof M. Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. J. Pharmacol. Exp. Ther. 249:1987;601-608.
3. Doheny H.C., Whittington M.A., Jefferys J.G.R., Patsalos P.N. Levetiracetam in a chronic model of epilepsy. Epilepsia. 38(suppl 8):1997;30.
4. Dunn A.A. A new iterative polyexponential curve fitting program. Comput. Methods Programs Biomed. 20:1985;269-275.
5. Gower A.J., Noyer M., Verloes R., Gobert J., Wulfert E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 222:1992;193-203.
6. Gower A.J., Hirsch E., Boehrer A., Noyer M., Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22:1995;207-213.
7. Kasteleijn-Nolst Trenite D.G.A., Marescaux C., Stodieck S., Edelbroek P.M., Oosting P.M. Photosensitive epilepsy: a model to study the effect of antiepileptic drugs. Evaluation of the piracetam analogue levetiracetam. Epilepsy Res. 25:1996;225-230.
8. Klockowski P.M., Levy G. Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats. J. Pharmacol. Exp. Ther. 244:1988;912-918.
9. Lolin Y.I., Ratnaraj N., Hjelm M., Patsalos P.N. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: phenytoin. Epilepsy Res. 19:1994;99-110.
10. Loscher W., Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 232:1993;147-158.
11. Loscher W., Honack D., Bloms-Funke P. The novel antiepileptic drug levetiracetam (ucbL059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in sustantia nigra pars reticulata. Brain Res. 735:1996;208-216.
12. Loscher W., Honack D., Rundfeldt C. Antiepileptic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 285:1998;474-479.
13. Margineanu D.G., Wulfert E. ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo. Eur. J. Pharmacol. 286:1995;321-326.
14. Margineanu D.G., Wulfert E. Inhibition by levetiracetam of a non-GABA A receptor-associated epileptiform effect of bicuculline in rat hippocampus. Br. J. Pharmacol. 122:1997;1146-1150.
15. Metzler, C.M., Weiner, D.L., 1988. A manual for PCNONLIN, Statistical Consultants, Lexington, KY, USA.
16. Noyer M., Gillard M., Matagne A., Henichart J.P., Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286:1995;137-146.
17. Patsalos P.N., Alavijeh M.S., Semba J., Lolin Y.I. A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): hematological and biochemical characterization and kinetic evaluation using carbamazepine. J. Pharmacol. Toxicol. Methods. 28:1992;21-28.
18. Patsalos P.N., Walker M.C., Ratnaraj N., Sander J.W.A.S., Shorvon S.D. The pharmacokinetics of levetiracetam (ucb L059) in partients with intractable epilepsy. Epilepsia. 36(Suppl. 4):1995;52.
19. Ratnaraj N., Doheny H.C., Patsalos P.N. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb L059) in serum or plasma by high performance liquid chromatography. Ther. Drug Monit. 18:1996;154-157.
20. Semba J., Curzon G., Patsalos P.N. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide. Br. J. Pharmacol. 108:1993;1117-11124.
21. Sharief M.K., Singh P., Sander J.W.A.S., Patsalos P.N., Shorvon S.D. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. J. Epilepsy. 9:1996;106-112.
22. Sills G.J., Leach J.P., Fraser C.M., Forrest G., Patsalos P.N., Brodie M.J. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur. J. Pharmacol. 325:1997;35-40.
23. Sokomba E.N., Patsalos P.N., Lolin Y.I., Curzon G. Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluid. Neuropharmacology. 27:1988;409-415.
24. Walker M.C., Patsalos P.N. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol. Ther. 67:1995;351-384.
25. Walker M.C., Tong X., Brown S., Shorvon S.D., Patsalos P.N. Comparison of single- and repeated-dose pharmacokinetics of diazepam. Epilepsia. 39:1998;283-289.